Shen Xun, Liu Jie, Lv Xianli, Li Youxiang
Beijing Neurosurgical Institute and Beijing Tiantan Hospital, Capital Medical University; Beijing, People's Republic of China - Neurosurgical Department, China Meitan General Hospital; Beijing, People's Republic of China -
Beijing Neurosurgical Institute and Beijing Tiantan Hospital, Capital Medical University; Beijing, People's Republic of China.
Interv Neuroradiol. 2014 Jul-Aug;20(4):495-501. doi: 10.15274/INR-2014-10046. Epub 2014 Aug 28.
This study reports the natural history of unruptured brain arteriovenous malformations (AVMs) and the risks involved in their endovascular management. A total of 242 patients at our center were enrolled in the study, which had retrospective and prospective components. We retrospectively assessed the morbidity and mortality related to endovascular management in 125 patients with unruptured AVMs. We prospectively assessed the natural history of unruptured AVMs in 117 patients with newly diagnosed unruptured AVMs; 48 of the patients had no history of seizure (Group 1), whereas 69 had a history of seizure from the lesion (Group 2). The retrospective group was also divided into patients with and without seizures. The cumulative rate of rupture of AVMs in Group 2 was less than 0.8% per year, while the rate was approximately sixfold higher (5.1% per year) in Group 1. The overall cumulative rate of rupture of AVMs was less than 3.0% per year. The overall rate of endovascular management-related morbidity and mortality was 10.6% in Group 2 and 11.9% in Group 1 at 30 days and was 25.9% and 13.6%, respectively, at one year. There was no independent predictor of a poor endovascular outcome. The likelihood of rupture of unruptured AVMs was exceedingly low among patients in Group 2 and was substantially higher among those in Group 1. The risk of morbidity and mortality related to endovascular management greatly exceeded the six-year risk of rupture among patients in Group 2. Endovascular management of an AVM should not be performed to eliminate or to improve seizure frequency.
本研究报告了未破裂脑动静脉畸形(AVM)的自然史及其血管内治疗所涉及的风险。我们中心共有242例患者纳入本研究,该研究包括回顾性和前瞻性两部分。我们回顾性评估了125例未破裂AVM患者血管内治疗相关的发病率和死亡率。我们前瞻性评估了117例新诊断的未破裂AVM患者未破裂AVM的自然史;其中48例患者无癫痫病史(第1组),而69例患者有该病变所致癫痫病史(第2组)。回顾性组也分为有癫痫发作和无癫痫发作的患者。第2组AVM的年累计破裂率低于0.8%,而第1组的破裂率约高6倍(每年5.1%)。AVM的总体年累计破裂率低于3.0%。第2组血管内治疗相关的总体发病率和死亡率在30天时为10.6%,在1年时分别为25.9%;第1组在30天时为11.9%,在1年时为13.6%。没有血管内治疗不良结局的独立预测因素。未破裂AVM在第2组患者中的破裂可能性极低,而在第1组患者中则显著更高。第2组患者中,血管内治疗相关的发病率和死亡率风险大大超过了六年的破裂风险。不应为消除或改善癫痫发作频率而对AVM进行血管内治疗。